{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:44:37Z","timestamp":1785915877946,"version":"3.56.0"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371877"],"award-info":[{"award-number":["82371877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["W2533208"],"award-info":[{"award-number":["W2533208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.trsl.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:42:06Z","timestamp":1780443726000},"page":"37-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Next-generation CAR-T cell engineering by Chinese scientists: Structural innovation, tumor microenvironment remodeling, and clinical translation"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-0591","authenticated-orcid":false,"given":"Muhammad Babar","family":"Khawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazala","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleem","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.trsl.2026.06.001_bib0001","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/fon-2019-0810","article-title":"Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis","volume":"16","author":"Liu","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2026.06.001_bib0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.3153","article-title":"CAR-T -cell therapy in large B-cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0004","article-title":"CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0005","article-title":"Bibliometric analysis of chimeric antigen receptor-based immunotherapy in cancers from 2001 to 2021","volume":"13 - 2022","author":"Ou","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s12672-025-03285-6","article-title":"Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis","volume":"16","author":"Li","year":"2025","journal-title":"Discover Oncology"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s12672-025-03360-y","article-title":"Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015\u20132024)","volume":"16","author":"Sweileh","year":"2025","journal-title":"Discover Oncology"},{"key":"10.1016\/j.trsl.2026.06.001_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840956","article-title":"A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021","volume":"13","author":"Miao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0009","article-title":"The 100 most influential studies in chimeric antigen receptor T-cell: a bibliometric analysis","volume":"2 - 2020","author":"Seo","year":"2020","journal-title":"Front Med Technol"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0010","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1007\/s00210-024-03258-6","article-title":"Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research","volume":"397","author":"Zhang","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557157","article-title":"Allogeneic CART progress: platforms, current progress and limitations","volume":"16","author":"Shokati","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-026-00899-y","article-title":"In vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","article-title":"Identification of NOXA as a pivotal regulator of resistance to CAR-T -cell therapy in B-cell malignancies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0014","article-title":"The third-generation anti-CD30 CAR-T -cells specifically homing to the tumor and mediating powerful antitumor activity","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.trsl.2026.06.001_bib0015","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10s","key":"10.1016\/j.trsl.2026.06.001_bib0016","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bulcan.2021.02.017","article-title":"CAR-T cells, from principle to clinical applications","volume":"108","author":"Bourbon","year":"2021","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","article-title":"Clinical development of CAR-T cell therapy in China: 2020 update","volume":"18","author":"Wei","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"10.1016\/j.trsl.2026.06.001_bib0018","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/imt-2020-0075","article-title":"Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Wang","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.trsl.2026.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102377","article-title":"Donor-derived Anti-CD19 CAR-T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial","volume":"67","author":"Luo","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(88)90025-7","article-title":"A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials","volume":"112","author":"Aebersold","year":"1988","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0023","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0024","doi-asserted-by":"crossref","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","article-title":"CAR-T -cell therapies in China: rapid evolution and a bright future","volume":"9","author":"Hu","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s41587-020-00749-8","article-title":"The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape","volume":"38","author":"Lyu","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0026","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","article-title":"Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience","volume":"108","author":"Sun","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0027","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","article-title":"Clinical development of CAR-T cell therapy in China: 2020 update","volume":"18","author":"Wei","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11427-016-5047-0","article-title":"Armed T cells with CAR for cancer immunotherapy","volume":"59","author":"Wei","year":"2016","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0029","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s12672-025-03282-9","article-title":"CAR-T cell therapy in china: innovations, challenges, and strategic pathways","volume":"16","author":"Yan","year":"2025","journal-title":"Discover Oncology"},{"key":"10.1016\/j.trsl.2026.06.001_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.omto.2020.04.008","article-title":"LunX-CAR-T cells as a targeted therapy for non-small cell lung cancer","volume":"17","author":"Hu","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0031","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcyt.2021.02.117","article-title":"Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19\/CD20 chimeric antigen receptor T cells","volume":"23","author":"Wang","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.trsl.2026.06.001_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trsl.2026.06.001_bib0034","article-title":"Bispecific c-met\/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","article-title":"Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy","volume":"6","author":"Mo","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2026.06.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101538","article-title":"Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Transpl Immunol"},{"issue":"14","key":"10.1016\/j.trsl.2026.06.001_bib0037","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.7150\/thno.84946","article-title":"A dendritic\/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.trsl.2026.06.001_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.omto.2023.07.007","article-title":"Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment","volume":"30","author":"Xia","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.trsl.2026.06.001_bib0039","article-title":"Reforming the chimeric antigen receptor by peptide towards optimized CAR-T cells with enhanced anti-cancer potency and safety","volume":"10","author":"Liu","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114949","article-title":"TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0042","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2026.06.001_bib0043","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0044","article-title":"Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D (bbz) CAR-T cells","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0045","article-title":"The third-generation anti-CD30 CAR-T -cells specifically homing to the tumor and mediating powerful antitumor activity","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0046","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.immuni.2024.11.005","article-title":"Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity","volume":"57","author":"Xu","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2026.06.001_bib0047","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0048","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR-T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer\/T cell lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0050","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem Biophys Rep"},{"issue":"17","key":"10.1016\/j.trsl.2026.06.001_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206856","article-title":"BiTE-secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0052","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41551-025-01450-4","article-title":"Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses","volume":"10","author":"Fan","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.trsl.2026.06.001_bib0053","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0054","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.3390\/ijms23105686","article-title":"Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy","volume":"23","author":"Shin","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0055","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","article-title":"Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0056","article-title":"Delivery of CD47 blocker sirp\u03b1-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Huanpeng","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0057","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0058","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1681\/ASN.2020030276","article-title":"Renal involvement and early prognosis in patients with COVID-19 pneumonia","volume":"31","author":"Pei","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0059","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR-T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0060","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-020-01085-1","article-title":"IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR-T cells","volume":"35","author":"Jiang","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0061","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR-T cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Canc Immun Immunother"},{"key":"10.1016\/j.trsl.2026.06.001_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121341","article-title":"IL-12 nanochaperone-engineered CAR-T cell for robust tumor-immunotherapy","volume":"281","author":"Luo","year":"2022","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0063","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14771","article-title":"Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro","volume":"41","author":"Xiong","year":"2021","journal-title":"Liver Int"},{"issue":"Pt B","key":"10.1016\/j.trsl.2026.06.001_bib0064","article-title":"IL-7 promotes CD19-directed CAR-T cells proliferation through miRNA-98-5p by targeting CDKN1A","volume":"124","author":"Yang","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"20","key":"10.1016\/j.trsl.2026.06.001_bib0065","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0066","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR-T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0067","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR-T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.trsl.2026.06.001_bib0068","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omtm.2020.08.008","article-title":"Safety and efficacy of an immune cell-specific chimeric promoter in regulating anti-PD-1 antibody expression in CAR-T cells","volume":"19","author":"Fang","year":"2020","journal-title":"Mol Ther Meth Clin Dev"},{"issue":"null","key":"10.1016\/j.trsl.2026.06.001_bib0069","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.2147\/CMAR.S260915","article-title":"EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer","volume":"Volume 12","author":"Zhou","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10637-020-00978-3","article-title":"Dual-function chimeric antigen receptor T cells targeting c-met and PD-1 exhibit potent anti-tumor efficacy in solid tumors","volume":"39","author":"Yuan","year":"2021","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0071","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12916-021-02161-8","article-title":"Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1\/PD-L1 pathway","volume":"19","author":"Shen","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.trsl.2026.06.001_bib0072","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00198-0","article-title":"Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth","volume":"8","author":"Qin","year":"2020","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0074","first-page":"1","article-title":"Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy","volume":"19","author":"Zhang","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.trsl.2026.06.001_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/sirp\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0076","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 blocker SIRPalpha-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.trsl.2026.06.001_bib0077","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.ymthe.2023.02.023","article-title":"CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0078","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","article-title":"Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.trsl.2026.06.001_bib0079","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.trsl.2026.06.001_bib0080","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.immuni.2023.09.006","article-title":"Releasing the brake: CTLA-4 loss turbocharges CAR-T cells","volume":"56","author":"Schelker","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2026.06.001_bib0081","first-page":"1023","article-title":"Chimeric CTLA4-CD28-CD3Z T cells potentiate antitumor activity against CD80\/CD86\u2013positive B cell malignancies","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0082","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0083","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0084","article-title":"Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.omto.2021.07.003","article-title":"CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells","volume":"22","author":"Li","year":"2021","journal-title":"Mol Ther Oncol"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0086","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.scib.2020.12.027","article-title":"Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C-C motif chemokine receptor 6","volume":"66","author":"Jin","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.trsl.2026.06.001_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115536","article-title":"Expressing IL-15\/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer","volume":"212","author":"Ruixin","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0088","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.3390\/ijms24065424","article-title":"Chemokine receptors CCR6 and PD1 blocking scFv E27 enhances anti-EGFR CAR-T therapeutic efficacy in a preclinical model of Human non-small cell lung carcinoma","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0089","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1007\/s00432-022-04509-w","article-title":"IL-2\/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K\/AKT and ERK1\/2 pathways","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0090","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03bab\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0091","first-page":"1","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Canc Immun Immunother"},{"issue":"44","key":"10.1016\/j.trsl.2026.06.001_bib0092","doi-asserted-by":"crossref","first-page":"18874","DOI":"10.1021\/jacs.0c08538","article-title":"Enhanced safety and antitumor efficacy of switchable dual chimeric antigen receptor-engineered T cells against solid tumors through a synthetic bifunctional PD-L1-blocking peptide","volume":"142","author":"Yang","year":"2020","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0093","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/acssynbio.1c00007","article-title":"Switchable CAR-T cells outperformed traditional antibody-redirected therapeutics targeting breast cancers","volume":"10","author":"Cao","year":"2021","journal-title":"ACS Synth Biol"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003176","article-title":"Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells","volume":"9","author":"Zhao","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0095","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/s41467-022-33793-w","article-title":"Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR-T cells via the CD70-CD27 axis","volume":"13","author":"Qin","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0096","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0097","article-title":"Human hyaluronidase PH20 potentiates the antitumor activities of Mesothelin-specific CAR-T cells against gastric cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0098","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2026.06.001_bib0099","article-title":"Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors","volume":"10","author":"Fan","year":"2020","journal-title":"Front Oncol"},{"issue":"51","key":"10.1016\/j.trsl.2026.06.001_bib0100","doi-asserted-by":"crossref","first-page":"56712","DOI":"10.1021\/acsami.0c15239","article-title":"Injectable porous microchips with oxygen reservoirs and an immune-niche enhance the efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Luo","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0101","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"issue":"18","key":"10.1016\/j.trsl.2026.06.001_bib0102","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3390\/cells11182863","article-title":"CAR-T-cell therapy for solid tumors positive for fibronectin extra domain B","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0103","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1186\/s12885-020-07180-x","article-title":"Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0104","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-022-03290-6","article-title":"Dominant-negative transforming growth factor-beta receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"10.1016\/j.trsl.2026.06.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202007494","article-title":"Nanoengineered CAR-T biohybrids for Solid tumor immunotherapy with microenvironment photothermal-remodeling strategy","volume":"17","author":"Chen","year":"2021","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0107","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007199","article-title":"Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"43","key":"10.1016\/j.trsl.2026.06.001_bib0108","article-title":"Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR-T cells for combination therapy","volume":"17","author":"Zhu","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.trsl.2026.06.001_bib0109","article-title":"A near-Infrared-II fluorescent nanocatalyst for enhanced CAR-T Cell therapy against solid tumor by immune reprogramming","author":"Li","year":"2023","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0110","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00432-022-04017-x","article-title":"CAR-T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer","volume":"148","author":"Zhu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-023-01467-9","article-title":"GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer","volume":"16","author":"Fan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0112","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40164-023-00450-x","article-title":"CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR-T cells in vitro","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.trsl.2026.06.001_bib0114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.omto.2022.06.003","article-title":"DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D","volume":"26","author":"Li","year":"2022","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0115","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.2147\/OTT.S247836","article-title":"Minicircle DNA-mediated CAR-T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo","volume":"Volume 13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004035","article-title":"Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.trsl.2026.06.001_bib0117","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","article-title":"Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells","volume":"27","author":"Nian","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"44","key":"10.1016\/j.trsl.2026.06.001_bib0118","doi-asserted-by":"crossref","first-page":"18874","DOI":"10.1021\/jacs.0c08538","article-title":"Enhanced safety and antitumor efficacy of switchable dual chimeric antigen receptor-engineered T cells against solid tumors through a synthetic bifunctional PD-L1-blocking peptide","volume":"142","author":"Yang","year":"2020","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0119","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/s41467-022-33968-5","article-title":"Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR-T cells against non-small cell lung cancer","volume":"13","author":"Cao","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0121","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2023.01.011","article-title":"Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"25","author":"Ma","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR-T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0124","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 Dual-targeted CAR-T -cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0125","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 Chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.trsl.2026.06.001_bib0126","article-title":"Humanized CD30-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against Hodgkin's Lymphoma cells","volume":"9","author":"Guo","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"13","key":"10.1016\/j.trsl.2026.06.001_bib0127","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/bloodadvances.2022008402","article-title":"SECTM1-based CAR-T cells enriched with CD7-low\/negative subsets exhibit efficacy in CD7-positive malignancies","volume":"7","author":"Wei","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.trsl.2026.06.001_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0129","article-title":"First-in-human trial of EphA2-redirected CAR-T -cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.trsl.2026.06.001_bib0130","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0131","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR-T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0132","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.trsl.2026.06.001_bib0133","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0134","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0135","series-title":"Safety and efficacy of chimeric antigen receptor T cells modified to target mesothelin and express PD-1 antibodies in patients with relapsed\/refractory solid cancers in a phase I trial","author":"Fang","year":"2020"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0136","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0137","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0138","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.802705","article-title":"Evaluation of nonviral piggyBac and lentiviral vector in functions of CD19chimeric antigen receptor T cells and their anti-tumor activity for CD19+ tumor cells","volume":"12","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0141","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR-T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0142","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/16078454.2021.1981534","article-title":"Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"26","author":"Zhang","year":"2021","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0143","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103508","article-title":"Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways","volume":"9","author":"Shao","year":"2022","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco.2018.04.02","article-title":"Chimeric antigen receptor T cells, a savior with a high price","volume":"7","author":"de Lima Lopes","year":"2018","journal-title":"Chin Clin Oncol"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0145","article-title":"CAR-T therapy in clinical practice: technical advances and current challenges","volume":"6","author":"Ren","year":"2022","journal-title":"Adv Biol (Weinh)"},{"key":"10.1016\/j.trsl.2026.06.001_bib0146","article-title":"Umbilical cord blood: a promising source for allogeneic CAR-T cells","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0147","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.apsb.2023.02.004","article-title":"Universal chimeric fc\u03b3 receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0148","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CM9.0000000000002476","article-title":"Challenges and optimal strategies of CAR-T therapy for hematological malignancies","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0149","doi-asserted-by":"crossref","first-page":"e942","DOI":"10.1016\/S2352-3026(22)00331-3","article-title":"Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China","volume":"9","author":"Li","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0150","doi-asserted-by":"crossref","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","article-title":"CAR-T -cell therapies in China: rapid evolution and a bright future","volume":"9","author":"Hu","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0151","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cpt.2625","article-title":"Analysis of patent and regulatory exclusivity for novel agents in China and the United States: a cohort study of drugs approved between 2018 and 2021","volume":"112","author":"Luo","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.trsl.2026.06.001_bib0152","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1311439","article-title":"Expediting drug development\u2014The FDA's new \u201cbreakthrough therapy\u201d designation","volume":"369","author":"Sherman","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0153","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","article-title":"Evolution of innovative drug R&D in China","volume":"21","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0154","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.trsl.2026.06.001_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103370","article-title":"Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020\u20132022","volume":"27","author":"Luo","year":"2022","journal-title":"Drug Discov Today"},{"issue":"10223","key":"10.1016\/j.trsl.2026.06.001_bib0156","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The lancet"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.trsl.2026.06.001_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215762","article-title":"CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia","volume":"542","author":"Zheng","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trsl.2026.06.001_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104342","article-title":"A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti-B-cell maturation antigen CAR-T cells","volume":"363","author":"Wang","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0160","article-title":"The chemokine receptor CCR8 is a target of chimeric antigen T cells for treating T cell malignancies","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0161","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0162","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/cas.14638","article-title":"Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro","volume":"111","author":"Liu","year":"2020","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0163","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.3390\/cancers12092612","article-title":"CD19-CAR-T cells bearing a KIR\/PD-1-based inhibitory CAR eradicate CD19+ HLA-C1\u2212 malignant B cells while sparing CD19+ HLA-C1+ healthy B cells","volume":"12","author":"Tao","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10223","key":"10.1016\/j.trsl.2026.06.001_bib0164","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-020-0824-y","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0166","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","article-title":"A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: cAR-modified T cell therapy based on CD30 mAb","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.trsl.2026.06.001_bib0167","article-title":"Characterization of the therapeutic effects of novel chimeric antigen receptor T cells targeting CD38 on multiple myeloma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0168","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti-CD5 directed CAR-T -cell against T-cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"issue":"22","key":"10.1016\/j.trsl.2026.06.001_bib0169","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR-T cells","volume":"6","author":"Yan","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","article-title":"Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas","volume":"15","author":"Ding","year":"2020","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0171","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.apsb.2023.02.004","article-title":"Universal chimeric fcgamma receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.trsl.2026.06.001_bib0172","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.trsl.2026.06.001_bib0173","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113919","article-title":"Nanobody-based CAR-T cells targeting intracellular tumor antigens","volume":"156","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0174","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-023-00438-7","article-title":"Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"18","key":"10.1016\/j.trsl.2026.06.001_bib0175","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2026.06.001_bib0176","article-title":"Reducing hinge flexibility of CAR-T cells prolongs survival In vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"23\u201324","key":"10.1016\/j.trsl.2026.06.001_bib0177","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1089\/hum.2023.144","article-title":"Chimeric antigen receptor-T cell therapy decreases distant metastasis and inhibits local recurrence post-surgery in mice","volume":"34","author":"Li","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0178","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1038\/s41467-022-32092-8","article-title":"T cell receptor beta-chain-targeting chimeric antigen receptor T cells against T cell malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2026.06.001_bib0179","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121872","article-title":"Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice","volume":"291","author":"Zhou","year":"2022","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0180","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00262-022-03195-4","article-title":"Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor","volume":"71","author":"Wang","year":"2022","journal-title":"Canc Immun Immunother"},{"issue":"11","key":"10.1016\/j.trsl.2026.06.001_bib0181","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0182","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003091","article-title":"Avidity-based selection of tissue-specific CAR-T cells from a combinatorial cellular library of CARs","volume":"8","author":"Ma","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.trsl.2026.06.001_bib0183","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121424","article-title":"A CAR-T -inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy","volume":"282","author":"Fan","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.trsl.2026.06.001_bib0184","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0185","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824643","article-title":"Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.trsl.2026.06.001_bib0186","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.2733","article-title":"MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma","volume":"9","author":"Mei","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0187","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/s41467-022-33968-5","article-title":"Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR-T cells against non-small cell lung cancer","volume":"13","author":"Cao","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.trsl.2026.06.001_bib0188","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","article-title":"Targeting PD-L1 in non-small cell lung cancer using CAR-T cells","volume":"9","author":"Liu","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.trsl.2026.06.001_bib0189","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.665970","article-title":"PTK7-Targeting CAR-T -cells for the treatment of lung cancer and other malignancies","volume":"12","author":"Jie","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0190","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0191","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.trsl.2026.06.001_bib0192","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR-T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0193","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR-T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0194","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trsl.2026.06.001_bib0195","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1111\/cas.15828","article-title":"Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.trsl.2026.06.001_bib0196","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-020-0183-x","article-title":"PSCA is a target of chimeric antigen receptor T cells in gastric cancer","volume":"8","author":"Wu","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.trsl.2026.06.001_bib0197","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.2147\/CMAR.S264358","article-title":"JAK-STAT domain enhanced MUC1-CAR-T cells induced esophageal cancer elimination","volume":"Volume 12","author":"Zhang","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0198","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300891620960223","article-title":"Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer","volume":"107","author":"Yu","year":"2021","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0199","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR-T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2026.06.001_bib0200","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211025503","article-title":"Incidence and risk factors associated with infection after chimeric antigen receptor T cell therapy for relapsed\/refractory B-cell malignancies","volume":"30","author":"Zhu","year":"2021","journal-title":"Cell Transplant"},{"key":"10.1016\/j.trsl.2026.06.001_bib0201","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.trsl.2026.06.001_bib0202","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.01.008","article-title":"Inhibition of cholesterol esterification enzyme enhances the potency of Human chimeric antigen receptor T cells against pancreatic carcinoma","volume":"16","author":"Zhao","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0203","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7-H3 as a target for CAR-T cell therapy in skull base chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0204","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","article-title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation","volume":"42","author":"Sun","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.trsl.2026.06.001_bib0205","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/cancers12010139","article-title":"Inhibition of PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma","volume":"12","author":"Cui","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.trsl.2026.06.001_bib0207","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR-T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2026.06.001_bib0209","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.016","article-title":"IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors","volume":"524","author":"Zou","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trsl.2026.06.001_bib0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573823","article-title":"Intercellular adhesion molecule-1 as target for CAR-T-cell therapy of triple-negative breast cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.trsl.2026.06.001_bib0211","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0004563220922255","article-title":"Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)","volume":"57","author":"Lippi","year":"2020","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0212","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immun"},{"issue":"1","key":"10.1016\/j.trsl.2026.06.001_bib0213","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003837","article-title":"Anti-tumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers","volume":"11","author":"Ba","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.trsl.2026.06.001_bib0214","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-20-0405","article-title":"Targeting triple-negative breast cancer with combination therapy of EGFR CAR-T cells and CDK7 inhibition","volume":"9","author":"Xia","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.trsl.2026.06.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jri.2020.103115","article-title":"Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells","volume":"139","author":"He","year":"2020","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.trsl.2026.06.001_bib0216","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110562","article-title":"Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer","volume":"131","author":"Zhang","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.trsl.2026.06.001_bib0217","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41401-020-00511-5","article-title":"Feasibility study of (68)Ga-labeled CAR-T cells for in vivo tracking using micro-positron emission tomography imaging","volume":"42","author":"Wang","year":"2021","journal-title":"Acta Pharmacol Sin"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:47:38Z","timestamp":1785912458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426001039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":217,"alternative-id":["S1931524426001039"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.06.001","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation CAR-T cell engineering by Chinese scientists: Structural innovation, tumor microenvironment remodeling, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}